Literature DB >> 9990696

Estimating the proportion of treatment effect explained by a surrogate marker.

P Flandre, Y Saidi.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 9990696     DOI： 10.1002/(sici)1097-0258(19990115)18:1<107::aid-sim965>3.0.co;2-p

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  5 in total

1.  Biomarkers and surrogate endpoints in kidney disease.

Authors:  Erum A Hartung
Journal:  Pediatr Nephrol       Date:  2015-05-16       Impact factor: 3.714

2.  Association of animal and plant protein intakes with biomarkers of insulin and insulin-like growth factor axis.

Authors:  Dong Hoon Lee; Fred K Tabung; Edward L Giovannucci
Journal:  Clin Nutr       Date:  2022-04-14       Impact factor: 7.643

Review 3.  Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.

Authors:  Qian Shi; Daniel J Sargent
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

4.  Evaluation of progressive neuroretinal rim loss as a surrogate end point for development of visual field loss in glaucoma.

Authors:  Felipe A Medeiros; Renato Lisboa; Linda M Zangwill; Jeffrey M Liebmann; Christopher A Girkin; Christopher Bowd; Robert N Weinreb
Journal:  Ophthalmology       Date:  2013-08-12       Impact factor: 12.079

Review 5.  Validity of sealant retention as surrogate for caries prevention--a systematic review.

Authors:  Steffen Mickenautsch; Veerasamy Yengopal
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.